WASHINGTON, Oct. 22, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted.
Key Third Quarter 2024 Results
Rainer M. Blair, President and Chief Executive Officer, stated, “Our team delivered strong third quarter results, including better-than-expected revenue growth. We were especially pleased with the continued positive momentum in our bioprocessing business and believe Cepheid gained market share in molecular testing again this quarter.”
Blair continued, “Looking ahead, we believe the combination of our leading portfolio and DBS-driven execution differentiates Danaher and provides a strong foundation for sustainable long-term value creation while helping to meaningfully improve human health.”
Fourth Quarter and Full Year 2024 Outlook
The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines.
For the fourth quarter 2024, the Company anticipates that non-GAAP core revenue will decline low-single digits year-over-year. For full year 2024, the Company continues to expect that non-GAAP core revenue will be down low-single digits year-over-year.
Conference Call and Webcast Information
Danaher will discuss its third quarter results and financial guidance for the fourth quarter and full year 2024 during its quarterly investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s website, www.danaher.com, under the subheading “Events & Presentations” and additional related materials will be posted to the same section of Danaher’s website. A replay of the webcast will be available in the same section of Danaher’s website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 800-245-3047 within the U.S. or by dialing +1 203-518-9765 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher’s earnings conference call (Conference ID: DHRQ324). A replay of the conference call will be available shortly after the conclusion of the call and until November 5, 2024. You can access the replay dial-in information on the “Investors” section of Danaher’s website under the subheading “Events & Presentations.”
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS
In addition to the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, as applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.
In addition, this earnings release, our Form 10-Q, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the “Investors” section of Danaher’s website (www.danaher.com) under the subheading “Quarterly Earnings.”
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the anticipated financial results for the fourth quarter and full year 2024, the Company’s positioning for sustainable long-term value creation and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2024. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
Three-Month Period Ended
Nine-Month Period Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Sales
$ 5,798
$ 5,624
$ 17,337
$ 17,485
Cost of sales
(2,397)
(2,349)
(7,021)
(7,230)
Gross profit
3,401
3,275
10,316
10,255
Operating costs:
Selling, general and administrative
expenses
(2,060)
(1,728)
(5,736)
(5,294)
Research and development
expenses
(383)
(362)
(1,142)
(1,096)
Operating profit
958
1,185
3,438
3,865
Nonoperating income (expense):
Other income (expense), net
102
(47)
7
(38)
Interest expense
(87)
(70)
(217)
(201)
Interest income
4
79
103
186
Earnings before income taxes
977
1,147
3,331
3,812
Income taxes
(159)
(207)
(518)
(712)
Net earnings from continuing
operations
818
940
2,813
3,100
Earnings from discontinued
operations, net of income taxes
—
189
—
585
Net earnings
818
1,129
2,813
3,685
Mandatory convertible preferred stock
dividends
—
—
—
(21)
Net earnings attributable to common
stockholders
$ 818
$ 1,129
$ 2,813
$ 3,664
Net earnings per common share from
continuing operations:
Basic
$ 1.13
$ 1.27
$ 3.83
$ 4.19
Diluted
$ 1.12
$ 1.26
$ 3.80
(a)
$ 4.15
Net earnings per common share from
discontinued operations:
Basic
$ —
$ 0.26
$ —
$ 0.80
Diluted
$ —
$ 0.25
$ —
$ 0.79
(a)
Net earnings per common share:
Basic
$ 1.13
$ 1.53
$ 3.83
$ 4.98
(a)(b)
Diluted
$ 1.12
$ 1.51
$ 3.80
(a)
$ 4.94
Average common stock and common
equivalent shares outstanding:
Basic
723.0
739.4
733.8
735.4
Diluted
729.4
745.9
740.1
742.1
(a)
Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.
(b)
Net earnings per common share amounts do not add due to rounding.
This information is presented for reference only. A complete copy of Danaher’s Form 10-Q financial statements is available on the Company’s website (www.danaher.com).
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share 1
Three-Month Period Ended
Nine-Month Period Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Diluted Net Earnings Per Common Share
From Continuing Operations (GAAP)
$ 1.12
$ 1.26
$ 3.80
$ 4.15
Amortization of acquisition-related
intangible assets A
0.57
0.49
1.65
1.49
Fair value net (gains) losses on
investments B
(0.14)
0.06
(0.01)
0.06
Impairments C
0.30
—
0.30
0.06
Acquisition-related items D
—
—
0.03
—
Tax effect of the above adjustments E
(0.14)
(0.10)
(0.37)
(0.30)
Discrete tax adjustments F
—
0.01
(0.06)
0.03
Rounding
—
—
—
0.01
Adjusted Diluted Net Earnings Per
Common Share From Continuing
Operations (Non-GAAP)
$ 1.71
$ 1.72
$ 5.34
$ 5.50
1
For the nine-month period ended September 29, 2023, each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock prior to their conversion on April 17, 2023. Net earnings from continuing operations per diluted common share for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
A
Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):
Three-Month Period Ended
Nine-Month Period Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Pretax
$ 414
$ 367
$ 1,223
$ 1,111
After-tax
341
301
1,008
909
B
Net (gains) losses on the Company’s equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended
Nine-Month Period Ended
September 27, 2024
September 29, 2023
September 27, 2024
September 29, 2023
Pretax
$ (103)
$ 48
$ (7)
$ 43
After-tax
(82)
36
(9)
32
C
Impairment charges related to a trade name in the Life Sciences segment recorded in the three and nine-month periods ended September 27, 2024 ($222 million pretax as reported in this line item, $169 million after-tax) and technology and other assets in the Biotechnology segment recorded in the nine-month period ended September 29, 2023 ($42 million pretax as reported in this line item, $32 million after-tax).
D
Costs incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc for the nine-month period ended September 27, 2024 ($25 million pretax as reported in this line item, $19 million after-tax).
E
This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
F
There were no discrete tax adjustments and other tax-related adjustments for the three-month period ended September 27, 2024 as excess tax benefits from stock-based compensation were offset by other discrete tax charges. Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 27, 2024, include net discrete tax benefits of $45 million related primarily to excess tax ben
